Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0005684 (
bladder cancer
)
16,431
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lymph node (LN) metastasis is the leading cause of
bladder cancer
-related mortality. Splicing factors facilitate cancer progression by modulating oncogenic variants, but it is unclear whether and how splicing factors regulate
bladder cancer
LN metastasis. In this study,
Polypyrimidine tract binding protein 1
(
PTBP1
) expression was found to relate to
bladder cancer
LN metastasis, and was positively correlated with LN metastasis status, tumor stage, histological grade, and poor patient prognosis. Functional assays demonstrated that
PTBP1
promoted
bladder cancer
cell migration, invasion, and proliferation in vitro, as well as LN metastasis and tumor growth in vivo. Mechanistic investigations revealed that
PTBP1
upregulated MEIS2-L variant to promote metastasis and increased expression of PKM2 variant to enhance proliferation by modulating alternative mRNA splicing. Moreover, overexpression of MEIS2-L or PKM2 could rescue the oncogenic abilities of
bladder cancer
cells and the expression of MMP9 or CCND1 respectively after
PTBP1
knockdown. In conclusion, our data demonstrate that
PTBP1
induces
bladder cancer
LN metastasis and proliferation through an alternative splicing mechanism.
PTBP1
may serve as a novel prognostic marker and therapeutic target for LN-metastatic bladder cancer.
...
PMID:Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM. 3074 45